Prolia (Denosumab) and Benzodiazepines Interaction

Why This Question Matters for Osteoporosis Patients

Patients prescribed denosumab (brand name Prolia) for osteoporosis are, by definition, at elevated fracture risk. Many of these same patients also take benzodiazepines for anxiety, insomnia, or muscle spasm. The overlap is not rare. A 2019 analysis of Medicare Part D claims found that 12.4% of women aged 65 and older receiving osteoporosis therapy had a concurrent benzodiazepine prescription [1]. The clinical question is straightforward: does combining these medications create a dangerous interaction, and if so, what kind?

The answer splits into two distinct domains. On the pharmacokinetic side, there is no interaction. On the pharmacodynamic side, the combination creates a compounding risk that deserves specific attention from prescribers and patients alike. The sections below break each domain apart with supporting evidence.

Pharmacokinetic Profile: No Metabolic Overlap

Denosumab is a fully human IgG2 monoclonal antibody that binds RANK ligand (RANKL), preventing osteoclast formation and bone resorption. Its elimination follows the same pathway as endogenous immunoglobulins: uptake and catabolism by the reticuloendothelial system [2]. It is not a substrate, inhibitor, or inducer of any cytochrome P450 isoenzyme. It does not interact with P-glycoprotein transporters. It does not undergo renal clearance. These properties mean denosumab cannot alter the plasma levels of co-administered small molecules through any conventional drug-drug interaction mechanism.

Benzodiazepines, by contrast, are small-molecule compounds metabolized primarily through hepatic CYP3A4 (alprazolam, midazolam, triazolam) or CYP2C19 (diazepam) pathways, with some agents undergoing direct glucuronidation (lorazepam, oxazepam, temazepam) [3]. Because denosumab does not participate in CYP-mediated metabolism at all, it cannot inhibit or induce the enzymes responsible for benzodiazepine clearance. The FDA-approved prescribing information for Prolia contains no listed drug interactions and states that "no formal drug-drug interaction studies have been conducted" because the antibody's clearance mechanism makes such studies unnecessary [2].

This is not a gap in the evidence. It is a pharmacologic certainty.

The Real Risk: Pharmacodynamic Fall Hazard

The concern with concurrent use is not about drug levels. It is about what happens when a patient who already has fragile bones takes a medication that impairs balance, coordination, and reaction time.

Benzodiazepines are among the most consistently identified medication classes linked to falls in older adults. A meta-analysis by Woolcott et al. (2009) pooling 22 studies found that sedative and hypnotic use was associated with a 47% increase in fall risk (OR 1.47 to 95% CI 1.35-1.62) [4]. The mechanism is multifactorial: benzodiazepines cause sedation, psychomotor slowing, reduced postural reflexes, and impaired proprioception. These effects are dose-dependent but present even at low doses in elderly patients.

Falls are the proximate cause of more than 90% of hip fractures [5]. A patient on denosumab has already been identified as having a T-score of -2.5 or worse, or has sustained a prior fragility fracture. Adding a benzodiazepine to this clinical picture does not create a drug interaction in the traditional pharmacologic sense. It creates a scenario where the medication prescribed to prevent fractures is working against a co-prescribed medication that makes fractures more likely to occur.

Risk Stratification: Which Patients Need the Most Attention

Not every patient on denosumab plus a benzodiazepine carries the same level of risk. Three patient profiles warrant heightened vigilance.

Profile 1: The chronic benzodiazepine user aged 75+. The FREEDOM trial, which established denosumab's fracture-reduction efficacy, enrolled women aged 60-90 with a mean age of 72.3 years. In that study, denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared to placebo (N=7,868) [6]. Those gains can be partially or fully offset if the patient sustains a mechanical fall from benzodiazepine-related impairment. The 2023 updated American Geriatrics Society (AGS) Beers Criteria explicitly lists all benzodiazepines as potentially inappropriate medications in adults aged 65 and older, citing increased risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes [7].

Profile 2: The new benzodiazepine initiation. Fall risk from benzodiazepines is highest in the first two weeks of therapy and after dose increases [4]. If a patient already receiving denosumab is started on a benzodiazepine, the prescribing clinician should specifically counsel about fall prevention during this high-risk window.

Profile 3: The patient on multiple CNS-active medications. Adding a benzodiazepine to an existing regimen that includes opioids, antihistamines, muscle relaxants, or gabapentinoids compounds fall risk beyond what any single agent produces. The STOPP/START criteria (version 3, 2023) flag concurrent use of two or more CNS depressants as a prescribing concern in older adults [8].

Specific Benzodiazepines and Their Relative Risk Profiles

Not all benzodiazepines are pharmacokinetically equivalent, and the choice of agent matters when fall risk is the primary concern.

Long-acting agents like diazepam (half-life 20-100 hours including active metabolites) and chlordiazepoxide (half-life 5-30 hours, active metabolite half-life up to 200 hours) accumulate substantially in older adults due to age-related increases in volume of distribution and decreased hepatic clearance [3]. These drugs carry the highest fall risk in geriatric populations. Short-acting agents that bypass CYP metabolism entirely, such as lorazepam (direct glucuronidation, half-life 10-20 hours) and oxazepam (direct glucuronidation, half-life 4-15 hours), produce less accumulation [3].

If a benzodiazepine is clinically necessary in a patient receiving denosumab, lorazepam or oxazepam at the lowest effective dose represents the most conservative pharmacologic choice from a fall-risk perspective. This preference aligns with geriatric prescribing guidelines that recommend avoiding long-acting benzodiazepines in adults over 65 [7].

The dose matters as much as the agent. A 2016 case-control study nested within the UK Clinical Practice Research Datalink found a dose-response relationship between benzodiazepine exposure and hip fracture risk, with adjusted odds ratios of 1.24 for low-dose, 1.42 for medium-dose, and 1.54 for high-dose use in adults aged 65+ [9].

Calcium and Vitamin D: A Shared Requirement That Connects Both Drugs

One practical intersection between denosumab therapy and benzodiazepine use involves calcium and vitamin D supplementation. The Prolia prescribing information requires that all patients receive adequate calcium (at least 1 to 000 mg daily) and vitamin D (at least 400 IU daily) during treatment [2]. Vitamin D deficiency must be corrected before initiating denosumab.

This matters because vitamin D deficiency itself is an independent risk factor for falls. A Cochrane review (Cameron et al., 2018) found that vitamin D supplementation reduced fall rates by approximately 28% in older adults who were vitamin D deficient at baseline [10]. Ensuring that denosumab patients maintain adequate vitamin D levels provides dual benefit: it supports the drug's mechanism of action on bone and it provides a partial counterweight to the fall risk introduced by concurrent benzodiazepine use.

Clinicians should verify 25-hydroxyvitamin D levels at denosumab initiation and annually thereafter, targeting a serum level of 30 ng/mL or higher per Endocrine Society guidelines [11].

Monitoring Recommendations for the Combination

No laboratory monitoring is required specifically because of the denosumab-benzodiazepine combination. There are no serum levels to check for interaction effects. The monitoring strategy is functional and clinical.

At each denosumab injection visit (every 6 months):

• Perform a structured fall-risk assessment. The CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm provides a validated framework [12].
• Review the benzodiazepine prescription: is it still indicated? Can the dose be reduced? Has the patient attempted a taper?
• Confirm calcium and vitamin D adherence and check serum 25-OH vitamin D if not measured in the prior 12 months.
• Screen for other CNS-depressant medications added since last visit.

After any fall:

• Obtain imaging as clinically indicated. Vertebral fractures may be clinically silent.
• Reassess the risk-benefit ratio of continued benzodiazepine therapy.
• Consider physical therapy referral for balance and strength training.

Deprescribing Benzodiazepines in Denosumab Patients

The strongest intervention for reducing the pharmacodynamic risk of this combination is eliminating or reducing the benzodiazepine. The 2018 Canadian Deprescribing Guidelines recommend gradual dose reduction (approximately 25% reduction every 2-4 weeks) rather than abrupt discontinuation to avoid withdrawal seizures and rebound anxiety [13].

For patients who cannot discontinue benzodiazepines entirely, switching from a long-acting to a short-acting, directly glucuronidated agent (lorazepam or oxazepam) and using the lowest effective dose is the next-best strategy. Non-pharmacologic alternatives for anxiety and insomnia, including cognitive behavioral therapy for insomnia (CBT-I), should be offered. CBT-I has demonstrated equivalent or superior long-term efficacy compared to benzodiazepines for chronic insomnia without fall risk, as shown in a randomized trial by Jacobs et al. (2004, N=63) published in the Archives of Internal Medicine [14].

What About Denosumab's Own Side Effect Profile?

Some patients and clinicians wonder whether denosumab itself contributes to fall risk. It does not. The FREEDOM trial reported no increase in dizziness, sedation, or balance impairment with denosumab compared to placebo [6]. The drug's side-effect profile centers on musculoskeletal pain (reported in 7.6% of denosumab patients vs. 6.4% placebo), hypocalcemia (particularly in patients with renal impairment), and rare events including osteonecrosis of the jaw and atypical femoral fractures with prolonged use [2].

Denosumab does not cross the blood-brain barrier. It has no CNS activity. Any fall or dizziness occurring in a patient on both medications should be attributed to the benzodiazepine (or other CNS-active agents) unless another cause is identified.

Special Populations

Renal impairment: Denosumab does not require dose adjustment in renal impairment, but patients with creatinine clearance <30 mL/min are at higher risk of hypocalcemia and should have calcium levels monitored within 14 days of each injection [2]. Some benzodiazepines (notably those with active renal-cleared metabolites like diazepam's oxazepam metabolite) may also accumulate. The combination in severe renal impairment requires careful calcium and fall-risk monitoring.

Glucocorticoid co-use: Patients taking chronic glucocorticoids may receive denosumab for glucocorticoid-induced osteoporosis. Glucocorticoids themselves cause myopathy and proximal weakness, which independently increase fall risk. Adding a benzodiazepine to this triad (glucocorticoid + denosumab + benzodiazepine) creates a triple-threat fall-risk scenario that should prompt aggressive non-pharmacologic fall-prevention interventions and strong consideration of benzodiazepine deprescribing.

Male patients: Denosumab is FDA-approved for osteoporosis in men at high fracture risk and for bone loss during androgen-deprivation therapy for prostate cancer [2]. The fall-risk concerns with concurrent benzodiazepine use apply equally to men, though this population is less frequently studied in osteoporosis fall-prevention trials.

Clinical Bottom Line

Denosumab and benzodiazepines occupy entirely separate pharmacologic compartments. No dose adjustment, timing separation, or laboratory monitoring is needed for the combination on pharmacokinetic grounds. The prescribing concern is strategic, not metabolic: a drug prescribed to prevent fractures is being given alongside a drug class proven to cause the falls that produce fractures. Every denosumab injection visit should include a direct conversation about whether the benzodiazepine is still necessary, and every patient on this combination should have a documented fall-prevention plan.